Randomized trial investigates the role of digital twins in personalized drug therapy, suggesting significant advancements in clinical practice.
Digital twins, pharmacometrics, artificial intelligence, individualized pharmacotherapy, and workforce development are becoming increasingly interconnected in clinical pharmacy and drug development. Digital twin-driven pharmacometrics integrates mechanistic modeling with machine learning to enable patient-specific drug therapy prediction, simulation, and optimization. Recent applications include explainable artificial neural network-based pharmacokinetic models, interpretable machine learning approaches for early safety predictions, and in silico clinical trial designs. Collectively, these approaches support efficient clinical research and advance individualized pharmacotherapy. The successful implementation of digital twins depends on technological innovation and workforce development, requiring professionals with integrated expertise in pharmacology, modeling, and data science.
No takes yet. Share an insight, caveat, or question.
Tsuji et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: